Ramucirumab
EGFR Inhibitor
DB05578
Approved Indication
For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
1
Targets
0
Resistance Mutations
8
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.
Details
DrugBank ID
DB05578 ↗
Approval Date
2014-04-21
Molecular Weight
— g/mol
Drug Class
EGFR Inhibitor
ATC Codes
L01XC21
Synonyms
—
ChEMBL
CHEMBL1743062 ↗
Drug References (DrugBank)